Novo Nordisk A/S Sponsored ADR (NVO)
Wegovy and Ozempic drive impressive prescription growth, says Citi
Analysts from Citi are bullish about the GLP-1 market, particularly within obesity and diabetes treatments, signaling a positive outlook for key players despite facing some supply constraints. According to Citi, there was an impressive 244% increase in total prescriptions for obesity drugs, such as Wegovy, and an 18% rise for diabetes medications, including Ozempic and Rybelsus.
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
It's in Novo Nordisk's best interest to produce more winning cardiometabolic drugs. To that end, it's inking collaboration deals with multiple early-stage biotechs.
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
On Thursday, Evotec SE EVO entered a technology development partnership with Novo Nordisk A/S NVO in cell therapy.
Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
Novo Nordisk is cutting a lot of deals with small biotechs. The latest deal seeks to develop gene-editing therapies, perhaps for obesity.
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy. Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies.
Lose Weight With Novo Nordisk Drugs, Gain Money With Stock
Some experts believe Novo Nordisk A/S NVO products not only help people lose weight and control diabetes, they can help treat the country's addiction crisis.
Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
Novo Nordisk's blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, according to a new study. The results suggest semaglutide, the active ingredient in Ozempic, could potentially become a new alternative treatment for opioid use disorder, which could help address the ongoing opioid epidemic.
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
Novo Nordisk (NVO) closed at $125.44 in the latest trading session, marking a +1.41% move from the prior day.
Healthy Returns: Weight loss drug Wegovy could face Medicare price negotiations next
Novo Nordisk's weight loss drug Wegovy could face Medicare price negotiations next. Meanwhile, Particle Health files an antitrust suit against Epic Systems.
Novo Nordisk CEO testifies before Senate on weight loss drug prices
CNBC's Angelica Peebles reports on Novo Nordisk's testimony before the Senate Health, Education, Labor, and Pensions Committee.
Novo Nordisk's Setback Won't Last: A Game-Changing Drug Emerges
Novo Nordisk NYSE: NVO took a hit on its stock price last week after it received bad news on one of its in-development treatments. At the same time, shares of big and small competitors rallied as a result.
